Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making rapid and successful advancements in the...more
In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact with unique receptors on disease-causing cells while avoiding interaction with...more
4/9/2025
/ Acquisitions ,
FDA Approval ,
Innovation ,
Inter Partes Review (IPR) Proceeding ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
USPTO
On January 6, 2025, the FDA released draft guidance on using artificial intelligence (AI) in regulatory decision-making for drugs and biological products. The draft guidance – the first of its kind from the agency – aims to...more
2/13/2025
/ Artificial Intelligence ,
Compliance ,
Corporate Counsel ,
Data Integrity ,
Digital Health ,
Food and Drug Administration (FDA) ,
Life Sciences ,
Pharmaceutical Industry ,
Regulatory Oversight ,
Regulatory Requirements ,
Risk Management
As 2024 draws to a close, several crucial developments — some aimed at modernizing long-standing legal practices, others addressing emerging challenges — have reached patent law.
Originally published in Law360 - December...more
12/23/2024
/ Administrative Procedure Act ,
Alice/Mayo ,
Appeals ,
Artificial Intelligence ,
Chevron Deference ,
Design Patent ,
Graham Factors ,
Intellectual Property Protection ,
International Trade Commission (ITC) ,
Inventions ,
Inventors ,
Loper Bright Enterprises v Raimondo ,
Obviousness ,
Patent Applications ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Prior Art ,
Rulemaking Process ,
SCOTUS ,
Statutory Interpretation ,
Tariff Act of 1930 ,
USPTO ,
Utility Patents
As a firm responsible for managing global portfolios for pharmaceutical companies, we closely follow and seek to stay abreast of developments regarding patentability in various jurisdictions. We recently reviewed the Unified...more
8/22/2024
/ Amgen v Sanofi ,
Corporate Counsel ,
Disclosure ,
Enablement Inquiries ,
Inventions ,
Patent Invalidity ,
Pharmaceutical Patents ,
Prior Art ,
Priority Patent Claims ,
Sanofi-Aventis ,
SCOTUS ,
Unified Patent Court
Following the U.S. Supreme Court’s invalidation of a counterpart U.S. patent in the same family for lack of enablement (21-757 Amgen Inc. v. Sanofi (05/18/23) (supremecourt.gov)), the UPC has now rendered a decision on its...more
The United States Patent and Trademark Office (USPTO) recently published new guidance on subject-matter eligibility as related to Artificial Intelligence (AI), opening a written comment window to respond with a deadline of...more
7/22/2024
/ Abstract Ideas ,
Alice/Mayo ,
Artificial Intelligence ,
Executive Orders ,
Foreign Jurisdictions ,
Intellectual Property Protection ,
Inventors ,
New Guidance ,
Patent-Eligible Subject Matter ,
Patents ,
Research and Development ,
SCOTUS ,
Training ,
UK ,
USPTO